| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453319 | Leukemia Research | 2018 | 26 Pages |
Abstract
CML prevalence in France is estimated at 2.5 per 100,000 inhabitants before the 1980s, with a progression up to 6 by 2002. Since 2002 this trend has increased further, with current and predicted prevalence reaching levels around 18 and 24 per 100,000 in 2018 and 2030 respectively. CML prevalence reaches 30 per 100,000 by 2050 when progression slows. Our simulations show that prevalence of CML is driven by both population aging and relative survival improvement. The grey area corresponds to the expected prevalence of CML.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Marc Delord, Stéphanie Foulon, Jean-Michel Cayuela, Philippe Rousselot, Julia Bonastre,